Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update
MoonLake Immunotherapeutics (NASDAQ:MLTX) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts.
MoonLake Immunotherapeutics (NASDAQ:MLTX) is placed eighth on our list of most promising stocks.
TheFly reported on February 26 that Goldman Sachs increased its price target on MLTX to $11 from $10 and maintained a Sell rating. The update followed the company’s fourth-quarter and full-year results, with cash expected to fund operations into the second half of 2027 under its Hercules Capital facility. Although MLTX provided pipeline updates, the firm continues to question the likelihood of regulatory approval for sonelokimab.
On February 22, MoonLake Immunotherapeutics (NASDAQ:MLTX) disclosed topline findings from the Phase 2 S-OLARIS study of SLK in individuals with radiographic and non-radiographic axial spondyloarthritis (axSpA). In the trial, 81% of treated patients (n=26, mNRI) achieved an ASAS40 response at Week 12, alongside more than 80% reaching clinically important improvement based on ASDAS-CRP.
Imaging assessments, which include SPARCC MRI of the sacroiliac joints and 18F-NaF PET scans, showed reductions in inflammation and osteoblast activity. Biomarker analyses indicated rapid and sustained suppression of inflammatory pathways, and the safety results aligned with prior studies without identifying new safety concerns. The company intends to advance SLK into further clinical development, with additional updates shared during its fourth-quarter and full-year results announcement.
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing novel Nanobody therapies, including sonelokimab, to treat inflammatory diseases like hidradenitis suppurativa and psoriatic arthritis, aiming to improve patient outcomes through advanced immune-targeted medicines.
While we acknowledge the potential of MLTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ripple Partner Reaches One Million People With Safe Water
NASDAQ TRADE HALT CONTINUES <UCFIW.O> REASON NOT AVAILABLE AT 03:58 AM
VIPCross-Asset Positioning Amid AI Earnings Scrutiny and the US Election
1. Markets diverged during the week. Between the October 23 and October 30 closes, BTC fell 4.78%, the Nasdaq 100 declined 1.98%, and gold and silver dropped 2.72% and 8.59%, respectively. The DAX, KOSPI, Nikkei 225 and Hang Seng advanced. We focus on differences in growth prospects, valuation sensitivity and risk exposures rather than applying a single directional view across assets. 2. Market reactions to Alphabet's and Intel's earnings brought returns on AI investment into focus. Attention is shifting from the scale of capital expenditure to revenue realization, margins and free cash flow. Lower interest rates can ease discount-rate pressure, but a sustained valuation recovery still requires support from both operating performance and financing conditions. 3. The November 3 US midterm elections and November 6 employment report are key events in the coming week. We monitor how post-election fiscal and legislative agendas may affect interest rates, the dollar and industry operating conditions. Our execution priorities are to manage leverage and concentration, retain margin and exit-liquidity buffers, and avoid treating a single political outcome as an automatic trading signal. 4. Following Binance's disclosure of a security incident, industry attention to endpoint protection, access segregation and coordinated incident response has increased. Key assets to monitor: BTC, the Nasdaq 100, crude oil and gold, alongside upcoming earnings from AAPL, AMD, PLTR, ARM, ANET and QCOM.
HYATT HOTELS CORP <H.N>: JEFFERIES RAISES TARGET PRICE TO $188 FROM $167
Crypto prices
More
